

**SCIENTIFIC PANEL ON
GENETICALLY MODIFIED ORGANISMS**
167th Panel Plenary meeting – OPEN to observers



13-14 November 2024
10:00-18:00 / 9:00-13:00
AGENDA

Location: Parma, EFSA, board room

Chair: Josep Casacuberta

Day 1 – 13th November

Time	No.	Item
10:00	1	Welcome and Apologies for absence
	2	Presentation of the Guidelines for Observers
	3	Adoption of the agenda
	4	Declarations of interest
	5	Report on written procedure since the 166th Plenary
5.1		Minutes of the 166 th Plenary meeting
	6	Scientific outputs for discussion and possible adoption
6.1		GMFF-2021-1530 (AP175) Application for authorisation of genetically modified maize DAS1131 submitted under Regulation (EC) No 1829/2003 by Corteva Agriscience EFSA-Q-2022-00410
6.2		Mandate on "Protein safety" EFSA-Q-2023-00664
6.3		Mandate on "GMA-NGT" EFSA-Q-2023-00050
	7	Scientific topics for discussion
7.1		Development of risk assessment methodology for RNAi-based GMPs EFSA-Q-2024-00613
7.2		Procurement on "in silico Toxicity" EFSA-Q-2024-00605
7.3		Procurement on "Allergenicity" EFSA-Q-2024-00292
	8	New Mandates
8.1		Applications
8.2		Mandates
18:00		<i>End of day 1</i>



Day 2 – 14th November 2024

Time	No.	Item
9:00	7	Scientific topics for discussion
	7.4	Procurement on “Processing of protein” EFSA-Q-2023-00659
	6	Scientific outputs for discussion and possible adoption
	6.4	GMFF-2023-21116 Application for authorisation of genetically modified MON 94637 soybean in accordance with Regulation (EC) No. 1829/2003 (AP188) EFSA-Q-2024-00054
	6.5	GMFF-2023-14732 Application for authorisation of genetically modified sugar beet KWS20-1 in accordance with Regulation (EC) No. 1829/2003 (AP184) EFSA-Q-2023-00378
	6.6	Application for authorisation of LBFLFK canola import in the European Union submitted under Regulation (EC) No 1829/2003 by BASF Agriculture Solutions (EFSA-GMO-DE-2019- 157) EFSA-Q-2019-00394 - CLOSED ITEM
	9	Feedback from the Scientific Committee/EC/EFSA
	10	AoB
	11	Questions from and answers to Observers
13:00		<i>End of the meeting</i>